Company / Working Capital
Alaunos Therapeutics, Inc. Working Capital History
FY2012-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$1.2M
FY2025
5-year range
$1.2M / $62.8M
FY2021-FY2025
Trend
-43.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Working Capital has declined for 5 consecutive years, from $112M in FY2020 to $1M in FY2025.
Based on SEC 10-K filings.
$1M in FY2025 with a 5-year CAGR of -59.8%.
Declined from $6M to $1M over the past 2 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- -65.9%
- 5-Year CAGR
- -59.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- Alaunos Therapeutics, Inc.'s working capital has declined for 5 consecutive years.
- 5-year CAGR of -59.8%, indicating a declining trend.
- In FY2025, working capital decreased 43.0% year-over-year.
- Peak working capital was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score -3.79 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.2M | -43.0% |
| FY2024 | $2.1M | -67.3% |
| FY2023 | $6.3M | -78.7% |
| FY2022 | $29.6M | -52.8% |
| FY2021 | $62.8M | -44.0% |
| FY2020 | $112.2M | +20.7% |
| FY2019 | $93.0M | +24.3% |
| FY2018 | $74.8M | +19.7% |
| FY2013 | $62.5M | +1.8% |
| FY2012 | $61.4M | -33.8% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026